22:58 · 10 āļāļĢāļāļŽāļēāļ„āļĄ 2023

BREAKING:Novavax on the wave after receiving $350 million for unused COVID shots📈

Novavax's (NVAX.US) share price jumped more than 20% after the biotech company said Canada had agreed to pay $350 million for Covid vaccines that were previously due to be delivered. The settlement, in the case of NVAX, is significant because the company's management expressed doubts about its viability earlier in the year. 

According to the SEC filing, the Canadian government's payment will be made in two equal instalments in 2023. It is worth mentioning that the vaccines for Covid-19 are the company's only commercial product. 

The company's shares are currently testing the limitation formed by the 100-day exponential moving average (purple curve). Source: xStation 5

21 āļāļĢāļāļŽāļēāļ„āļĄ 2026, 15:49

Samsung āļāđ‰āļēāļ§āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļĒāļļāļ„ â€œPhysical AI” āđāļĨāļ°āļŦāļļāđˆāļ™āļĒāļ™āļ•āđŒ āļŦāļļāđ‰āļ™āļžāļļāđˆāļ‡āļ‚āļķāđ‰āļ™ 3% ðŸĪ–

21 āļāļĢāļāļŽāļēāļ„āļĄ 2026, 14:34

āļ›āļāļīāļ—āļīāļ™āđ€āļĻāļĢāļĐāļāļāļīāļˆ: āļ•āļĨāļēāļ”āđāļĢāļ‡āļ‡āļēāļ™āļ­āļąāļ‡āļāļĪāļĐāđāļ‚āđ‡āļ‡āđāļāļĢāđˆāļ‡ āļˆāļąāļšāļ•āļēāļ”āļąāļŠāļ™āļĩāļ„āļ§āļēāļĄāđ€āļŠāļ·āđˆāļ­āļĄāļąāđˆāļ™ ZEW āļ‚āļ­āļ‡āđ€āļĒāļ­āļĢāļĄāļ™āļĩ

20 āļāļĢāļāļŽāļēāļ„āļĄ 2026, 15:27

DeepSeek Moment āļ„āļĢāļąāđ‰āļ‡āđƒāļŦāļĄāđˆāļāļģāļĨāļąāļ‡āļĄāļē? Moonshot AI āļ—āđ‰āļēāļ—āļēāļĒāļĒāļąāļāļĐāđŒāđƒāļŦāļāđˆāđƒāļ™āļ§āļ‡āļāļēāļĢ AI

20 āļāļĢāļāļŽāļēāļ„āļĄ 2026, 08:36

āļ‚āđˆāļēāļ§āđ€āļ”āđˆāļ™āļ§āļąāļ™āļ™āļĩāđ‰ 20 āļ.āļ„.

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ